10-K: Black Hawk Acquisition Faces Going Concern Amid Vesicor Deal

Black Hawk Acquisition Corporation reported its fiscal year 2025 results, revealing a definitive business combination agreement with Vesicor Therapeutics, Inc. but also significant going concern uncertainties and internal control weaknesses.

Summary

• Black Hawk Acquisition Corporation, a Cayman Islands exempted company, was incorporated on September 28, 2023, for the purpose of effecting a business combination.
• On April 26, 2025, the company entered into a Business Combination Agreement with Vesicor Therapeutics, Inc., an early development stage biotechnology corporation focused on p53-based cancer therapeutics.
• The transaction values Vesicor at a pre-money equity value of $70 million, with existing Vesicor shareholders rolling over 100% of their equity into the combined company.
• The Initial Public Offering (IPO) closed on March 22, 2024, raising $69,000,000 from 6,900,000 units at $10.00 per unit.
• A private placement simultaneously generated $2,355,000 from the sale of 235,500 units to the Sponsor at $10.00 per unit.
• Initially, $69,345,000 from the IPO and Private Placement proceeds was placed in a U.S.-based trust account.
• Shareholders approved an extension of the business combination deadline to December 22, 2026, requiring monthly deposits of $150,000 into the trust account.
• In connection with the extension, 4,775,923 public ordinary shares were redeemed, resulting in a payment of approximately $51.0 million and reducing the trust account balance to approximately $22.7 million.
• The company reported net income of $1,329,557 for the year ended November 30, 2025, a decrease from $1,915,703 in 2024.
• As of November 30, 2025, the company had cash of $39,521 and a working capital deficit of $1,431,443.
• Management identified substantial doubt about the company's ability to continue as a going concern due to liquidity issues and dependence on completing the business combination.
• A material weakness in internal controls over financial reporting was identified due to inadequate segregation of duties and insufficient written policies and procedures.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a highly concerning report, primarily due to the explicit 'going concern' warning, significant shareholder redemptions, and identified material weaknesses in internal controls, which overshadow the progress on the business combination.

Positives

• A definitive Business Combination Agreement has been secured with Vesicor Therapeutics, Inc., providing a clear path for the company's future operations.
• Shareholders approved an extension of the business combination deadline until December 22, 2026, allowing more time to complete the transaction.
• The management team possesses extensive experience in executive leadership, management consulting, and mergers and acquisitions, which is expected to aid in value creation.
• The company's structure as a publicly listed entity offers an attractive alternative to traditional IPOs for target businesses, potentially offering a less expensive and more certain path to public markets.
• The company reported a net income of $1,329,557 for the fiscal year ended November 30, 2025.

Negatives

• Management has identified substantial doubt about the company's ability to continue as a going concern due to liquidity needs and dependence on completing the business combination.
• A significant portion of public shares (4,775,923) were redeemed, resulting in a payment of approximately $51.0 million and reducing the trust account balance from $69,345,000 to approximately $22.7 million.
• The company reported a working capital deficit of $1,431,443 as of November 30, 2025.
• A material weakness in internal controls over financial reporting was identified due to inadequate segregation of duties and insufficient written policies and procedures.
• Extension payments due in December 2025 and January 2026 were funded after their respective due dates, indicating ongoing liquidity challenges.
• Net income decreased from $1,915,703 in the year ended November 30, 2024, to $1,329,557 in the year ended November 30, 2025.
• The company has no revenue and has incurred losses since inception from formation and operating costs.

Risks

• The company's ability to select an appropriate target business or businesses and complete its initial business combination is uncertain.
• There are risks associated with the performance of the prospective target business or businesses, particularly an early-stage biotechnology company like Vesicor.
• The company faces challenges in retaining or recruiting key officers, employees, or directors following the initial business combination.
• Officers and directors may have conflicts of interest due to their time allocation to other businesses.
• The company's ability to obtain additional financing to complete the initial business combination is uncertain.
• There is a risk of potential liquidity issues and trading challenges for the company's public securities.
• The trust account may not be entirely immune to claims of third parties, potentially reducing funds available for public shareholders.
• If the initial business combination is not completed by December 22, 2026, the company will liquidate, and public shareholders may suffer a material loss.
• Claims of creditors could take priority over public shareholders in the event of liquidation.
• The company may encounter intense competition from other entities when identifying and selecting a target business.
• There is a limited ability to evaluate the target's management team, and future management may lack the necessary skills for a public company.
• Shareholders may not have the ability to approve the initial business combination if not required by law or stock exchange rules.
• Purchases of securities by insiders could reduce the public float and beneficial holders, potentially affecting Nasdaq listing.
• The company may be affected by numerous risks inherent in a financially unstable or early-stage target business.
• Lack of business diversification after completing a single business combination could subject the company to negative economic, competitive, and regulatory developments.
• New regulations or policies in China could restrict the remittance of RMB if the target business operates there.
• Global social and political circumstances (e.g., U.S.-China trade tensions, geopolitical conflicts) may materially and adversely affect the company's ability to consummate a business combination or the target's operations.

Future Outlook

The company intends to consummate its initial business combination with Vesicor Therapeutics, Inc., subject to customary closing conditions, regulatory approvals, and shareholder approvals. Following the business combination, the company may retain all available funds and future earnings to fund development and growth, and therefore does not expect to pay cash dividends in the foreseeable future. Management anticipates incurring increased expenses as a public company and for due diligence related to the business combination, expecting to generate non-operating income from interest on marketable securities in the trust account. The company plans to implement remediation steps to improve internal control over financial reporting, including expanding review processes for complex securities and accounting standards, enhancing access to accounting literature, identifying third-party professionals, and considering additional staff.

Management Comments

• "We believe our management team is well positioned to identify attractive risk-adjusted returns in the marketplace and that our professional contacts and transaction sources... will enable us to pursue a broad range of opportunities."
• "Our management believes that its collective ability to identify and implement value creation initiatives has been an essential driver of past performance and will remain central to its differentiated acquisition strategy."
• "We intend to focus our search for an initial business combination on private companies that have compelling economics and clear paths to positive operating cash flow, significant assets, and successful management teams that are seeking access to the U.S. public capital markets."
• "Management has determined that these conditions [liquidity needs, dependence on completing business combination] raise substantial doubt about the Company’s ability to continue as a going concern."
• "As of the issuance date of these financial statements, the required extension payments have been funded and the Company is current under its amended and restated memorandum and articles of association."

Industry Context

StockSavvy.ai notes that the SPAC market has seen increased redemptions and challenges in completing business combinations, making Black Hawk's significant redemptions and going concern warning indicative of broader industry headwinds. The pursuit of a biotechnology target like Vesicor Therapeutics aligns with a trend of SPACs seeking high-growth, innovative sectors, but also exposes the company to the inherent risks of early-stage development and regulatory hurdles common in the biotech industry.

Comparison to Industry Standards

• The significant redemptions (over 69% of public shares) are higher than the average SPAC redemption rates observed in recent years, which have typically ranged from 50-70% but can vary widely. This indicates a lack of investor confidence in the proposed deal or the SPAC's ability to execute.
• The pre-money equity valuation of Vesicor at $70 million for an early development stage biotechnology company is within the range for similar biotech startups, but its ultimate success is highly dependent on clinical trial outcomes and regulatory approvals, which are inherently risky compared to more mature industry players.
• The identified material weakness in internal controls is a red flag, contrasting with best practices for public companies, which emphasize robust internal control environments to ensure financial reporting reliability.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material litigation or other legal proceedings.
• Not aware of any legal proceeding, investigation, or claim that has a more than remote possibility of having a material adverse effect on the business, financial condition, or results of operations.

Related Party Transactions

• The Sponsor (Black Hawk Management LLC) initially purchased founder shares for $25,000 and 235,500 Private Units for $2,355,000.
• The company pays an affiliate of the Sponsor $10,000 per month for office space and administrative services.
• The Sponsor, officers, and directors are reimbursed for out-of-pocket expenses incurred on the company's behalf.
• The Sponsor agreed to make extension payments, funded via unsecured convertible promissory notes (June Note, September Note, and February 2026 Convertible Note).
• Vesicor Therapeutics, Inc. (the target company) contributed $575,000 as extension fees, recorded as 'Due to target company'.
• The Sponsor has agreed to be liable to the company if claims by vendors or prospective target businesses reduce the trust account below $10.05 per public share, with certain exceptions.

Stakeholder Impact

• Shareholders: Significant redemptions (over 69%) have reduced the value of the trust account per share. The going concern warning and internal control weaknesses pose substantial risks to future investment value. The business combination with Vesicor offers potential for future growth but is subject to execution risks and the company's precarious financial state.
• Employees (of combined entity): The filing mentions the potential for management team members to remain with the combined company and receive compensation, but no specific impact on the broader employee base is detailed. Successful completion of the business combination could provide stability and growth opportunities for Vesicor's employees.
• Customers/Suppliers (of combined entity): No direct impact is mentioned in the filing, but successful completion of the business combination could provide Vesicor with necessary capital for growth and operations, potentially benefiting its future customers and suppliers.
• Creditors: The trust account is generally protected from creditor claims, but the going concern warning and working capital deficit indicate potential challenges in meeting operational liabilities outside the trust. The Sponsor has indemnification obligations for certain claims against the trust account, offering some protection.

Next Steps

• Consummate the business combination with Vesicor Therapeutics, Inc., subject to customary closing conditions, regulatory approvals, and shareholder approvals.
• Vesicor Therapeutics, Inc. will reincorporate into Delaware, and BH Merger Sub, Inc. will merge with Vesicor, with the combined company listed on Nasdaq under the name Vesicor.
• Implement remediation steps to improve internal control over financial reporting, including expanding review processes, enhancing access to accounting literature, identifying third-party professionals, and considering additional staff.
• Continue making monthly extension payments of $150,000 into the trust account until December 22, 2026, to extend the business combination deadline.
• Identify and appoint a new director who qualifies as an audit committee financial expert following the passing of Mr. Brandon Miller.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a substantial working capital deficit and an explicit 'going concern' warning from management and auditors. The significant redemptions (over 69%) have drastically reduced the trust account, limiting the capital available for the business combination. Furthermore, the identified material weakness in internal controls raises concerns about financial reporting reliability. While a business combination agreement with Vesicor Therapeutics is in place, the company's precarious financial position and operational weaknesses make it a high-risk investment with a strong likelihood of further value erosion or even liquidation if the combination fails.

Keywords

SPAC, Business Combination, Vesicor Therapeutics, Biotechnology, Cancer Therapeutics, SEC Filing, 10-K, Financial Report, Going Concern, Internal Controls, Trust Account, Redemptions, Nasdaq, Merger, Acquisition, Corporate Governance, Financial Performance